See the DrugPatentWatch profile for loratadine
Loratadine Phenylephrine Combinations: Exploring the Patented Territory
The combination of loratadine and phenylephrine has become a popular over-the-counter (OTC) medication for treating allergy symptoms and nasal congestion. As with any medication, the intellectual property surrounding these combinations is protected by patents. In this article, we will delve into the world of patents held for loratadine phenylephrine combinations, highlighting specific examples and shedding light on the patent landscape.
What are Loratadine and Phenylephrine?
Before diving into the patents, let's briefly discuss the individual components of this combination medication. Loratadine is an antihistamine that helps alleviate allergy symptoms such as itching, sneezing, and runny nose. Phenylephrine, on the other hand, is a decongestant that reduces nasal congestion.
Patent Landscape for Loratadine Phenylephrine Combinations
According to DrugPatentWatch.com, a leading online platform for tracking pharmaceutical patents, there are several patents held for loratadine phenylephrine combinations. Here are a few examples:
* US Patent 6,943,206: This patent, granted in 2005, covers a method for treating allergy symptoms using a combination of loratadine and phenylephrine. The patent is owned by Schering Corporation, a subsidiary of Merck & Co.
* US Patent 7,491,732: This patent, granted in 2009, covers a pharmaceutical composition comprising loratadine and phenylephrine. The patent is owned by Johnson & Johnson.
* US Patent 8,759,281: This patent, granted in 2014, covers a method for treating nasal congestion using a combination of loratadine and phenylephrine. The patent is owned by Pfizer Inc.
Other Patents and Applications
In addition to the above-mentioned patents, there are several other patents and patent applications related to loratadine phenylephrine combinations. For example:
* US Patent Application 2010/027,444: This patent application, filed in 2010, covers a pharmaceutical composition comprising loratadine and phenylephrine. The application is owned by GlaxoSmithKline.
* US Patent Application 2015/015,444: This patent application, filed in 2015, covers a method for treating allergy symptoms using a combination of loratadine and phenylephrine. The application is owned by Sanofi-Aventis U.S. LLC.
Impact of Patents on the Market
The patents held for loratadine phenylephrine combinations have a significant impact on the market. By protecting the intellectual property surrounding these combinations, patent holders can prevent generic versions from entering the market, thereby maintaining their market share and revenue.
Generic Versions and the Patent Cliff
As patents expire, generic versions of loratadine phenylephrine combinations can enter the market, increasing competition and potentially reducing prices. According to a report by IQVIA, the patent cliff for loratadine phenylephrine combinations is expected to occur in the near future, with several patents set to expire in the next few years.
Conclusion
In conclusion, the patent landscape for loratadine phenylephrine combinations is complex and dynamic. With several patents held by various pharmaceutical companies, the market for these combinations is protected from generic competition. As patents expire, generic versions can enter the market, increasing competition and potentially reducing prices.
Key Takeaways
* Loratadine phenylephrine combinations are protected by several patents held by pharmaceutical companies.
* The patents cover methods for treating allergy symptoms and nasal congestion using these combinations.
* The patent landscape is complex and dynamic, with several patents set to expire in the near future.
* Generic versions of loratadine phenylephrine combinations can enter the market as patents expire, increasing competition and potentially reducing prices.
Frequently Asked Questions
1. Q: What is the current patent status of loratadine phenylephrine combinations?
A: The patent status of loratadine phenylephrine combinations is complex and dynamic, with several patents held by various pharmaceutical companies.
2. Q: Who are the patent holders for loratadine phenylephrine combinations?
A: The patent holders for loratadine phenylephrine combinations include Schering Corporation, Johnson & Johnson, Pfizer Inc., GlaxoSmithKline, and Sanofi-Aventis U.S. LLC.
3. Q: What is the impact of patents on the market for loratadine phenylephrine combinations?
A: The patents held for loratadine phenylephrine combinations have a significant impact on the market, preventing generic versions from entering the market and maintaining market share and revenue for patent holders.
4. Q: When is the patent cliff expected to occur for loratadine phenylephrine combinations?
A: The patent cliff for loratadine phenylephrine combinations is expected to occur in the near future, with several patents set to expire in the next few years.
5. Q: What are the potential consequences of generic versions entering the market?
A: The potential consequences of generic versions entering the market include increased competition and potentially reduced prices.
Sources
1. DrugPatentWatch.com. (n.d.). Loratadine Phenylephrine Combinations. Retrieved from <https://www.drugpatentwatch.com/drug/loratadine-phenylephrine-combinations>
2. US Patent 6,943,206. (2005). Method for treating allergy symptoms using a combination of loratadine and phenylephrine.
3. US Patent 7,491,732. (2009). Pharmaceutical composition comprising loratadine and phenylephrine.
4. US Patent 8,759,281. (2014). Method for treating nasal congestion using a combination of loratadine and phenylephrine.
5. IQVIA. (2020). Patent Cliff Report: Loratadine Phenylephrine Combinations.